Loading...
Docoh

Talaris Therapeutics (TALS)

Talaris Therapeutics, Inc. is a late-clinical stage biopharmaceutical company developing investigational, one-time, allogeneic cell therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, MA, and its cell processing facility in Louisville, KY.

TALS stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 May 22
12 Aug 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 22.79M 22.79M 22.79M 22.79M 22.79M 22.79M
Cash burn (monthly) (no burn) (no burn) 6.14M 4.74M 5.43M 3.94M
Cash used (since last report) n/a n/a 27.12M 20.96M 23.98M 17.39M
Cash remaining n/a n/a -4.33M 1.83M -1.19M 5.4M
Runway (months of cash) n/a n/a -0.7 0.4 -0.2 1.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
29 Jul 22 Scott Requadt Common Stock Buy Acquire P No No 4.25 39,382 167.37K 508,680
28 Jul 22 Scott Requadt Common Stock Buy Acquire P No No 4.25 3,090 13.13K 469,298
26 Jul 22 Scott Requadt Common Stock Buy Acquire P No No 4.24 5,528 23.44K 466,208
25 Jul 22 Nader Francois Common Stock Other Acquire J Yes No 0 138,500 0 386,932
25 Jul 22 Nader Francois Common Stock Other Dispose J No No 0 138,500 0 0
22 Jul 22 Scott Requadt Common Stock Buy Acquire P No No 3.7497 9,444 35.41K 460,680
21 Jul 22 Nader Francois Common Stock Buy Acquire P No No 3.72 36,500 135.78K 138,500
21 Jul 22 Nader Francois Common Stock Other Acquire J Yes No 0 248,432 0 248,432
21 Jul 22 Nader Francois Common Stock Other Dispose J Yes No 0 248,432 0 87,735
20 Jul 22 Nader Francois Common Stock Buy Acquire P No No 3.62 52,000 188.24K 102,000
13F holders Current Prev Q Change
Total holders 53 54 -1.9%
Opened positions 6 13 -53.8%
Closed positions 7 9 -22.2%
Increased positions 14 21 -33.3%
Reduced positions 14 7 +100.0%
13F shares Current Prev Q Change
Total value 482.13M 651.96M -26.0%
Total shares 42.3M 43.01M -1.7%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
BX Blackstone 8.09M $79.6M 0.0%
Blackstone Holdings II 8.09M $123.69M 0.0%
Viking Global Investors 3.29M $32.37M 0.0%
Longitude Capital Partners III 3.22M $45.64M 0.0%
Qiming U.S. Ventures Management 2.93M $28.86M 0.0%
Citadel Advisors 2.66M $26.21M +0.1%
BLK Blackrock 2.43M $23.95M +1.6%
Artal 2.06M $20.31M 0.0%
Qiming U.S. Healthcare GP II 1.83M $25.96M 0.0%
Eventide Asset Managment 1.56M $15.36M 0.0%
Largest transactions Shares Bought/sold Change
Avidity Partners Management 0 -455.04K EXIT
Norges Bank 0 -272.61K EXIT
STT State Street 261.47K +75.46K +40.6%
Hillhouse Capital Advisors 698.8K -63.09K -8.3%
BLK Blackrock 2.43M +38.45K +1.6%
Sectoral Asset Management 228.62K -31.95K -12.3%
Geode Capital Management 270.86K +25.04K +10.2%
Logos Global Management 306.24K -22.78K -6.9%
Nicholas Investment Partners 22.5K +22.5K NEW
Susquehanna International 17.21K +17.21K NEW

Financial report summary

?
Competition
Quoin Pharmaceuticals

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: ACA, adulterated, bespoke, bio, bioresearch, bluebird, borrow, borrowing, cast, CDPA, Chemistry, China, classification, collateralized, collusion, Colorado, counterfeit, CPA, destination, enhanced, EU, exit, faulty, Geopolitical, goal, governor, implicit, instability, interactive, interoperable, intervene, mark, masking, military, mistake, noncancelable, omicron, overhaul, override, reevaluate, regime, remote, residency, retrospective, RSU, Russia, segregation, simple, stolen, substantive, supersede, supplementary, tracing, UK, Ukraine, unfit, unrest, vaccination, version, Virginia, warfare, weaker, withdrawn, witnessed
Removed: abbreviated, acceptability, accessibility, acquired, addressed, afford, aimed, amendment, ancillary, assigned, ATRA, attaining, attempted, August, Banc, began, bifurcation, billed, BPCIA, bridge, broadening, bulk, canceled, capita, capitated, Category, charged, Circuit, Columbia, command, comparative, confirmation, congressional, consolidation, constitutionality, convenience, Cooperation, CPT, creating, declare, delaying, demonstrating, denied, deregulation, detachable, direction, dispersed, disposition, dissolution, DRG, ease, easier, embedded, En, enactment, evidenced, exercisable, extinguished, Favored, fifteenth, formula, fraction, fractional, freestanding, fundamental, FYs, gap, imply, importation, incentivize, initially, Innovation, insert, interchangeable, introduction, involuntary, Kingdom, KY, LDTK, legally, list, lowering, mandated, mandatory, methodology, metropolitan, mezzanine, MFN, modeled, multiplying, Nation, nationwide, nonassessable, Northern, notably, NTAP, opined, optimal, outlier, overturned, overturning, pathway, performing, permitted, Petition, pharmacoeconomic, pharmacy, pose, practice, predetermined, President, prolonged, prominent, proportion, propose, ratably, Rebate, reconsider, redeemed, redemption, reexamining, refine, regional, regular, regulate, Rehearing, reissued, remanded, removing, repeal, resuming, retired, revision, ruling, scaled, Secretary, separately, shutdown, SPA, specialty, substituted, supervision, surviving, Switzerland, Taxpayer, tertiary, thereon, timed, traditional, Tranche, Trump, unallocated, unconstitutional, unit, unnecessary, unpaid, upheld, utilization, voted, withdrew